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ABSTRACT
It has recently been shown that certain oligodeoxy-
nucleotides (ODNs) designed as catalytic DNA
molecules (DNAzymes) exhibit potent cytotoxicity
independent of RNA-cleavage activity in a number
of cell lines. These cytotoxic ODNs all featured a 50
G-rich sequence and induced cell death by a TLR9-
independent mechanism. In this study, we examined
the sequence and length dependence of ODNs for
cytotoxicity. A G-rich sequence at the 50 terminus of
the molecule was necessary for cytotoxicity and the
potency of ODNs with active 50 sequences was
length dependent. Cytotoxicity appeared to be
generally independent of 30 sequence composition,
although 30 sequences totally lacking G-nucleotides
were mostly inactive. Nucleolin, elongation factor
1-alpha (eEF1A) and vimentin were identified as
binding to a cytotoxic ODN (Dz13) using protein pull-
down assays and LC-MS/MS. Although these pro-
teins have previously been described to bind G-rich
ODNs, the binding of eEF1A correlated with cyto-
toxicity, whereas binding of nucleolin and vimentin
did not. Quiescent non-proliferating cells were
resistant to cytotoxicity, indicating cytotoxicity
may be cell cycle dependent. Although the exact
mechanism of cytotoxicity remains unknown,
marked potency of the longer (
T 25nt) ODNs in
particular, indicates the potential of these molecules
for treatment of diseases associated with abnormal
cell proliferation.
INTRODUCTION
Single-stranded oligodeoxynucleotides (ODNs) and in
particular certain G-rich ODNs have been widely reported
to have eﬀects on cells ranging from the induction of senes-
cence and aging (1) to inhibition of proliferation (2–4).
In some cases, secondary structure formation of
ODNs (e.g. G-quadruplexes) facilitates the recognition by
cellular protein(s) thus leading to cytotoxicity (5). In other
cases, anti-proliferative activity of ODNs is related to the
ability of the ODN to bind speciﬁc cellular proteins
independent of secondary structure (6,7). Known targets
of G-rich oligodeoxynucleotides include the human ribo-
somal protein L7a (8), nucleolin (9,10), elongation factor
1A (7,11), STAT3 (12) and growth factors (13).
DNAzymes are single-stranded DNA molecules that are
able to cleave RNA in a site-speciﬁc manner (14). The
molecules consist of a 50 and 30 binding arm and a
catalytically active core region. The stability and activity
of the DNAzymes in vitro make them a useful tool for
gene silencing, and a number of diﬀerent therapeutic
applications have been proposed (14). We recently showed
that the cellular eﬀects of some ODNs, originally designed
as DNAzymes against the transcription factors c-jun and
c-myc, were not due to the cleavage of the target mRNA
(15). Indeed, DNAzymes such as Dz13 (c-jun) and Rs6
(c-myc) and their catalytically inactive controls were
cytotoxic when transfected into several cultured cell lines
at concentrations as low as 10–50nM (15). These cyto-
toxic ODNs all featured G-rich regions at the 50 extremity
suggesting that this sequence element is required for
cytotoxicity. Although this cytotoxicity did not appear to
be dependent on the formation of G-quadruplexes
and other secondary structures (15), replacement of
any of the three contiguous guanosines of Dz13 with
7-deaza-guanosine abolished cytotoxicity. We therefore
postulated that the 50 extremity sequence element is
necessary for cytotoxicity and may be involved in
mediating speciﬁc interactions with cellular proteins.
The aims of the present article were to clarify
the sequence elements or ‘motifs’ required for cyto-
toxicity, to investigate the activity of various cytotoxic
ODNs on diﬀerent cell types, to determine the culture
conditions required for cytotoxicity, and ﬁnally, to
identify proteins that selectively bind to these cytotoxic
molecules.
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Oligodeoxynucleotides
HPLC-puriﬁed oligodeoxynucleotides were purchased
from Sigma and Trilink Biotechnologies. Stock
solutions were made up to a concentration of 50mM
in nuclease-free water and stored at  208C. The oligo-
deoxynucleotides used are listed in Table 1. The
30 biotinylated and 50 Oregon-Green labeled congeners
of Dz13 had the identical deoxyribonucleotide sequence
to DT1549 (Table 1) in which the 30-30T inversion of
Dz13 is missing.
Cellculture
Human dermal microvascular endothelial (HMEC-1) cells
were maintained in MCDB131 medium (Gibco) contain-
ing 10% foetal bovine serum (FBS), 2mM L-glutamine,
1mg/ml hydrocortisone (Sigma) and 10ng/ml epidermal
growth factor (EGF; Sigma) with or without 5U/ml
penicillin–streptomycin. Rat vascular smooth muscle
(RSMC), human embryonic kidney (HEK-293), HCT116
human colon cancer, NIH3T3 mouse ﬁbroblast and
human retinal pigmented epithelium (ARPE-19) cells
were cultured in DMEM F12 medium (Gibco)
Table 1. Oligodeoxynucleotides investigated
Name Sequence Comments
 
Dz13 CGGGAGGAAGGCTAGCTACAACGAGAGGCGTTG(30-30T) Dz13 (19)
DT1549 CGGGAGGAAGGCTAGCTACAACGAGAGGCGTTG Dz13 without 30 inversion
DT1501 CTGGAGGAAGGCTAGCTACAACGAGAGGCGTTG(30-30T) Dz13 with T in 50 arm instead of G
Dz13scr GCGACGTGAGGCTAGCTACAACGAGTGGAGGAG(30-30T) Dz13 scrambled
DT1309h CGGGAGGAAGGCTAGCTACAACGAGAGGCGTTG-B DT1549 with 30 biotin
DT1310c GCGACGTGAGGCTAGCTACAACGAGTGGAGGAG-B Dz13scr with 30 biotin instead of inversion
DT1530 CGGGAGGAA (30-30T) 50 sequence of Dz13
DT1531 CGGGAGGAAAGCAACATCGATCGG (30-30T) DT1530+inverted catalytic core
DT1532 CGGGAGGAAGGCTAGCTACAACGA (30-30T) DT1530+catalytic core
DT1536 CGGGAGGAAGGCTAGCTACAAGCAGAGGGCTTG (30-30T) Dz13 with CG in tail changed to GC
DT1537 CGGGAGGAAGGCTAGCACACAGAGGGTCATGGT (30-30T) Dz13 with scrambled tail
DT1538 CGGGAGGAAGN23 (30-30T) Dz13 50 sequence+random mix of nucleotides
DT1539 CGGGAGGAAGA23 (30-30T) Dz13 50 sequence plus polyA tail
DT1544 CGGGAGGAAGN5 Dz13 50 sequence+5 random bases
DT1545 CGGGAGGAAGN10 Dz13 50 sequence+10 random bases
DT1546 CGGGAGGAAGN15 Dz13 50 sequence+15 random bases
DT1547 CGGGAGGAAGN20 Dz13 50 sequence+20 random bases
DT1548 CGGGAGGAAGN25 Dz13 50 sequence+25 random bases
DT1552 CGGGAGGAAGH25 Dz13 50 sequence+25A, C or T
DT1553 CGGGAGGA N27 Reduced 50 Dz13+27 random bases
DT1554 CGGGAG N29 Reduced 50 Dz13+29 random bases
DT1555 CGGG N31 Reduced 50 Dz13+31 random bases
DT1570 CGGGAGGAAGTAGTAGTAGTAGTAGTAGTAGTAG Dz13 50 sequence+(TAG)8
DT1571 CGGGAGGAAGTAGGATTAGGATTAGGATTAGGAT Dz13 50 sequence+(TAGGAT)4
DT1572 GGGAGGAAAGN5 Modiﬁed 50 sequence+5 random bases
DT1573 GGGAGGAAAGN10 ’’ + 10 random bases
DT1574 GGGAGGAAAGN15 ’’ + 15 random bases
DT1575 GGGAGGAAAGN20 ’’ + 20 random bases
DT1576 GGGAGGAAAGN25 ’’ + 25 random bases
Rs6 (DT1556) TGAGGGGCAGGCTAGCTACAACGACGTCGTGA(30-30C) c-myc DNAzyme (29)
DT1533 TGAGGGGCA(30-30T) 50 extremity of Rs6 plus terminal inverted T
DT1534 TGAGGGGCAAGCAACATCGATCGG (30-30T) 50 extremity of Rs6 and inverted catalytic core
DT1535 TGAGGGGCAGGCTAGCTACAACGA (30-30T) 50 extremity of Rs6 and catalytic core
DT1600 N12CGGGAGGAAGN13 Dz13 50 motif in middle of random mix
DT1601 N25CGGGAGGAAG Dz13 50 motif at 30 end of random mix
DT1602 N25GAAGGAGGGC Dz13 50 motif inverted at 30 end of random mix
DT1557 TGAGGGGCAGN25 Rs6 50 sequence+25 random bases
DT1558 TGAGGGGCN27 Reduced 50 Rs6+27 random bases
DT1559 TGAGGGN29 Reduced 50 Rs6+29 random bases
DT1560 TGAGN31 Reduced 50 Rs6+31 random bases
DT1565 OG-CGGGAGGAAGGCTAGCTACAACGAGAGGCGTTG Oregon-Green labelled DT1549
GT(DT1605) TGTTTGTTTGTTTGTTTGTTTGTTTGT GT-ODN (11)
GRO29A (DT1563) TTTGGTGGTGGTGGTTGTGGTGGTGGTGG Nucleolin-binding ODN (24)
20AG AGGGAGGGAGGAAGGGAGGG G-rich ODN (17)
DT1591 AGGGAGGGAGGAAGGG Length variant (16-mer) of 20AG
DT1592 AGGGAGGGAGGAAGGGAGGGAGGG Length variant (24-mer) of 20AG
DT1593 AGGGAGGGAGGAAGGGAGGGAGGGAGGG Length variant (28-mer) of 20AG
DT1594 AGGGAGGGAGGAAGGGAGGGAGGGAGGGAGGG Length variant (32-mer) of 20AG
DT1595 AGGGAGGGAGGGAGGGAGGGAGGG AGGG repeat ODN
NT36 (DT1577) AAGAGGTGGTGGAGGAGGTGGTGGAGGAGGTGGAGG ATM-inducing ODN (23)
 number in brackets indicates reference number.
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Transfectionand cellular assays
Cells were seeded in 96-well black MicroClear plates
(Greiner) (4 10
3 cells/well) or 6-well plates
(1.2 10
5 cells/well) in growth medium containing 5%
FBS for HMEC-1, HCT116, HEK-293, NIH3T3 and
ARPE-19 cells or 10% FBS for RSMC cells. Cells were
transfected 24h after seeding with diﬀerent concentrations
of ODNs in triplicate using FuGene6 (Roche) as
previously described (15). Cell survival was assessed 48h
post-transfection in the 96-well plate format using the Cell
Titer
TM-Blue cell viability assay (Promega) as previously
described (15). Brieﬂy, culture medium was replaced with
100ml OptiMEM and 20ml of Cell-titer
TM blue reagent
and incubated for 2h at 378C. Fluorescence was measured
at 544EX/590EM using FLUOstar OPTIMA (BMG
Labtechnologies). For the cell density experiments,
ARPE-19, NIH3T3 or HMEC-1 cells were seeded at
densities of 4000 and 50000 cells per well in 96-well plates
and transfected with 0–200nM ODN in triplicate.
Transfection eﬃciencies at the 2 cell densities were
determined in duplicate in 60mm dishes using a
50-oregon green ODN (DT1565; Table 1) in a single
experiment. The 60mm dishes were seeded with a similar
number of cells/cm
2 as for the 96-well plates for
both seeding densities. For low density transfection,
2.6 10
5 cells/dish were seeded while for high density
transfection 3.25 10
6 cells/dish were seeded. Fluore-
scence of mock and DT1565-transfected cells was
measured 48h post-transfection using ﬂuorescence-
activated cell sorting (FACS).
Proteinextraction
Cells were washed twice with PBS and total proteins
extracted using MPER (Pierce) or RIPA (150mM NaCl,
0.1% w/v sodium dodecyl sulphate, 1% v/v Nonidet
P-40, 0.5% w/v sodium deoxycholate, 50mM Tris-HCl
pH 8). Subcellular proteins were extracted using the
ProteoExtract kit (Calbiochem). All extractions were
performed in the presence of EDTA-free protease
inhibitors (Roche). Cellular debris was removed by
centrifugation at 10 000g for 20min at 48C.
Proteinpull-down assays
Protein pull-down assays were performed using oligo-
deoxynucleotides as ‘bait’ in order to identify
Dz13-binding proteins. Dynabeads-Streptavidin (Dynal)
were washed twice in 2  Buﬀer A (10mM Tris-HCl,
1mM EDTA, 2M NaCl, pH 7.4). Beads (0.5ml) were
resuspended in 1ml 2  Buﬀer A to a ﬁnal concentration
of 5mg/ml beads. For in vitro assays, beads were incubated
in an equal volume of 2mM3 0 biotinylated congeners of
Dz13 or Dz13scr (DT1309h and DT1310c respectively,
Table 1) made up in Buﬀer B (20mM HEPES, 100mM
KCl, 0.2mM EDTA, 0.01% v/v NP-40, 10% v/v glycerol,
pH 7.5) and the mixture incubated at room temperature
for 10min with gentle mixing. The beads were washed
with 3 1ml Buﬀer B prior to addition of protein.
Protein extract (up to 1mg) was incubated with the
bead–DNA mixture for 10min at room temperature with
shaking. For the majority of protein pull-downs, the beads
were washed with 20 1ml Buﬀer B following incubation
with protein extract and proteins were eluted by two
washes with 1mM Dz13 or Dz13scr at room temperature.
In one experiment, the elutions were performed with
10mM Dz13 or Dz13scr. In between each elution, the
beads were washed with 3 1ml Buﬀer B.
To test whether the same proteins eluted with other
ODNs of interest an experiment was undertaken in which
the bead preparation, protein incubation and washing
steps were performed as described above. Following
washing of the beads, non-speciﬁc proteins were eluted
by 2 5min incubation with 1mM non-biotinylated
Dz13scr and the beads washed again with 3 1ml
Buﬀer B. This bead preparation was split into six identical
samples and proteins eluted by 2 5min incubations with
1mM ODN (Dz13, NT36, DT1501, Rs6, DT1595 or GT).
The resulting sample supernatants were collected and
analysed and each of the bead samples was again washed
with 3 1ml Buﬀer B and proteins eluted with 1mM
Dz13. This experiment was performed twice.
For in situ protein pull-down assays, cells were
transfected with 100nM biotinylated congeners of Dz13
or Dz13scr (i.e. DT1309h and DT1310c) for 24h. Beads
were washed three times with 1ml Buﬀer B and
resuspended at 5mg/ml prior to incubation for 10min at
room temperature with protein extracts prepared from
these cells using MPER. Following incubation, beads
were washed with 20 1ml Buﬀer B and resuspended
in 20ml Buﬀer B. Washing and elution steps were then
performed as described above.
Protein analysis
Fractions generated from pull-down assays were concen-
trated in a Centricon 10000 Mwt cutoﬀ 0.5ml centrifugal
device (Millipore) at 13 800g for 70min at 158C. Proteins
(from cell extracts or concentrated pull down fractions)
were denatured at 708C for 10min in 4  Loading Buﬀer
(Invitrogen), loaded onto NuPAGE 4–12% bis-tris
acrylamide gels (Invitrogen) and electrophoresed at
140V in MOPS-SDS running buﬀer. Following electro-
phoresis proteins were either silver-stained as described by
Rabilloud et al. (16) or transferred to a PVDF membrane
at 30V for 2h. Membranes were blocked in 3% BSA
in TBST (10mM Tris pH 8, 30mM NaCl, 0.05% v/v
Tween-20) for 1h at room temperature. Primary anti-
bodies were incubated at concentrations recommended
by the manufacturers for 1h at room temperature or
overnight at 48C in 5% skim milk-TBST. Membranes
were washed 3 5min in TBST and incubated for 1h
at room temperature with horseradish peroxidase con-
jugated antibodies (1:2000 in 5% skim milk-TBST;
DakoCytomation). Membranes were washed 3 5min in
TBST and visualized by chemiluminescence using ECL
(Amersham) and Hypersensitive ﬁlm (Amersham). The
following commercially available antibodies were used:
EF1A (CBK-KK1; Upstate Biotechnology), vimentin
(V9; Sigma) and STAT3 (F-2; Santa-Cruz Biotechnology).
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Total protein was digested by incubating 100 ml of sample,
25mlo f1 0 m MN H 4HCO3 and 1 mg trypsin at 378C for
16h. The digested peptides were loaded onto a C18
precolumn (500mm 2mm, Michrom Bioresources) using
H2O:CH3CN (98:2, 0.1% formic acid, buﬀer A) at
20ml/min. After a 10min wash, the pre-column was
switched (Switchos) in-line with an analytical column
containing C18 RP silica (PEPMAP, 75mm 15cm,
LC-Packings) or a fritless C18 column (75mm  12cm).
Peptides were eluted using a linear gradient of buﬀer A
to H2O:CH3CN (40:60, 0.1% formic acid-buﬀer B) at
200nl/min over 60min. The column was connected via
a fused silica capillary to a low volume tee (Upchurch
Scientiﬁc) where high voltage (2300V) was applied and
a nano electrospray needle (New Objective) or fritless
column outlet was positioned  1cm from the oriﬁce of an
API QStar Pulsar i hybrid tandem mass spectrometer
(Applied Biosystems). The QStar was operated in an
information-dependent acquisition mode. A TOF-MS
survey scan was acquired (m/z 350–1700, 0.5s) and the
two largest precursors (counts 410) sequentially selected
by Q1 for MS/MS analysis (m/z 50–2000, 2.5s).
A processing script generated data suitable for submission
to the database search programs. CID spectra were
analysed using Mascot MS/MS ion search (Matrix
Science). The criteria were: trypsin digestion allowing
up to 1 missed cleavage, oxidation of methionine, peptide
tolerance of 1.0Da and MS/MS tolerance of 0.8Da.
A Mascot score418 indicated identity.
RESULTS
Motif experiments
Variants of Dz13 and other selected DNAzymes, which
reduce proliferation in HMEC-1 cells but do not act
through cleavage of the RNA substrate, were designed in
order to elucidate the sequence requirements for cytotox-
icity. First, a set of oligodeoxynucleotides containing
regions of the Dz13 sequence was designed in order to
identify any requirement for an active motif. ODNs
corresponding to the 50 sequence of the ﬁrst 9 bases of
Dz13 (DT1530), this 50sequence plus the 10–23 catalytic
core (15bp) in the reverse orientation (DT1531) and the
50sequence plus the catalytic core in the correct orientation
(DT1532) were tested. All of these were substantially less
active than Dz13 (data not shown), suggesting that either
length or some other sequence requirement had not been
met. Similar results were obtained with the corresponding
ODN based on the 50 Rs6 sequence (DT1533-5, Table 1;
Figure S1a).
In order to elucidate the requirements of the tail for
cytotoxicity, Dz13 analogues of the same length but with
modiﬁed 30 tail sequences were tested (Table 1). These
included both CG dinucleotides in the 30 tail changed to
GC (DT1536), the ﬁrst 16 bases of Dz13 plus scrambled
tail (DT1537), a pool of ODNs all consisting of the ﬁrst
10 bases of Dz13 followed by a random mix of nucleotides
in tail sequence (DT1538) and the ﬁrst 10 bases of Dz13
followed by a polyA tail (DT1539). The polyA-tailed
Dz13 analogue (DT1539) exhibited no cytotoxicity in
HMEC-1 cells whereas DT1536 demonstrated intermedi-
ate cytotoxicity (Figure 1A). Both the scrambled tail
analogue (designed to remove the tail hairpin structure)
and the mixture of random-tailed oligodeoxynucleotides
had activity that was indistinguishable from Dz13,
indicating minimal sequence requirements for the 30 tail
in these 33-mer oligodeoxynucleotides.
To elucidate the positional requirement for a 50 G-rich
element, three pools of ODNs featuring the 50 motif from
Dz13 (ﬁrst 10 bases) were constructed with either the
50 motif in the middle of a random sequence pool, at the
30 end or at the 30 end in reverse order (DT1600-1602,
Table 1). None were signiﬁcantly cytotoxic, although
some activity was noted for the 30 reverse motif ODN
(Figure 1B). This suggests that the motif may also be
recognized in the 30 to 50 direction or that part of the
activity relates to the rest of the molecule. In any case, this
experiment conﬁrmed that the optimal placement for the
G-rich sequence of Dz13 is at the 50 end.
Given the lack of activity of the shorter variants
(DT1530–DT1532), the next experiment sought to clarify
the length requirement for the observed cytotoxicity.
This was tested by using ODN pools containing the ﬁrst
10 bases of Dz13 and 5, 10, 15, 20 or 25 random bases
(DT1544-48, Table 1). Cytotoxicity was concentration
and length dependent with only the 35-mer ODN pool
(DT1548) matching the potency of Dz13 (Figure 1C), thus
conﬁrming the role of the tail length. A similar result was
obtained with DT1572-6, which are based on a slightly
diﬀerent 50 sequence (data not shown).
Given previous results indicating that potency was
dependent on a relatively unbiased nucleotide composition
of the 30 tail, a new 35-mer ODN was tested in which
the random tail was composed only of A, C and T bases
(DT1552). This ODN was essentially devoid of cytotoxic
activity over the concentration range tested (data not
shown). These results indicate that the tail sequence has
no particular sequence requirements but that potency
is dependent on a relatively unbiased nucleotide repre-
sentation, including some G content.
A set of 35-mer oligodeoxynucleotides were designed
and synthesized in order to identify the minimal 50 motif
required for activity. This set comprised pools of
oligodeoxynucleotides for which the ﬁrst 10 bases of the
Dz13 50 G-rich sequence (plus a 25 random base tail;
DT1548) was progressively reduced (DT1553–DT1554) to
the ﬁrst 4 bases of this sequence plus a 31 base tail
(DT1555). Only DT1553 (ﬁrst 8+27 random) and
DT1548 (ﬁrst 10+25 random) retained full activity
(Figure 1D). The corresponding experiment with the Rs6
sequence (DT1557–60) produced gradated cytotoxicity
proﬁles with activity increasing with increased retention
of the 5’ Rs6 sequence (Figure S1b).
The Dz13 50 G-rich sequence, when extended with tail
sequences of TAG and TAGGAT repeat elements
(DT1570 and DT1571, respectively) had reduced activity
relative to Dz13 (data not shown). These tail sequences
were speciﬁcally free of C to prevent the formation of GC
clamps and possibly more complex secondary structures.
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oligodeoxynucleotides are capable of inducing cytotox-
icity under the same conditions in HMEC-1 cells including
the 20AG ODN described by Cogoi et al. (17). We
examined whether extension of this sequence in a manner
analogous to the Dz13 experiments would inﬂuence
cytotoxic activity. Consistent with the Dz13 results,
16- (DT1591), 24- (DT1592), 28- (DT1593) and 32-mer
(DT1594) variants of the 20-mer 20AG yielded length-
dependent cytotoxic activities with the longest two
molecules having similar proﬁles (data not shown).
Activity of Dz13 incontact-inhibited cells
Given their potent cytotoxic activity against proliferating
cells, Dz13 and the other cytotoxic oligodeoxynucleotides
could be of use in several disease states. Dz13 has been
reported as being active in several preclinical models of
disease including ocular angiogenesis (18), vascular
intimal proliferation (19) and cancer (20), which are all
diseases where inappropriate proliferation is present.
To investigate any possible diﬀerential activity relative
to non-proliferating cells, we examined the activity in two
additional cell lines that display contact inhibition, namely
ARPE-19 and NIH-3T3. In particular, ARPE-19 cells
form diﬀerentiated, polarized monolayers in vitro (21)
similar to that present in normal retinal epithelium. As
shown in Figure 2A, proliferating ARPE-19 cells were
sensitive to Dz13-induced cytotoxicity with an IC50
between 50 and 100 nM, whereas Dz13scr was inactive.
Dz13 cytotoxicity in ARPE-19 cells was abrogated over
that concentration range by increasing the cell seeding
density to 50 000 cells/well, at which seeding density the
cells grew to a uniform dense monolayer. Similar results
were obtained for the murine ﬁbroblast 3T3 cells, which
are also contact-inhibited and for HMEC-1 cells, which
form multilayered sheets at maximal conﬂuence (data not
shown). To rule out reduced transfection as the cause for
this eﬀect, repeat experiments were scaled up and
transfection eﬃciency was determined using a ﬂuorescent
50-OregonGreen-488 congener of Dz13 (DT1565; Table 1),
which was complexed with Fugene6 and transfected at a
ﬁnal concentration of 100 nM. DT1565 had reduced
cytotoxicity compared to Dz13 (data not shown), which
reduced the confounding eﬀects of toxicity on analysis,
and the transfection eﬃciency as determined by FACS
Figure 1. Cytotoxic activity of Dz13 analogues in HMEC-1 cells. The oligodeoxynucleotides (Table 1) were tested in HMEC cells and transfected at
a range of concentrations and cell survival measured 48h later. Cell survival as a percentage of untransfected cells is shown +/  SD from two
independent experiments. (A) Investigation into the 30 tail sequence required for cytotoxicity: Dz13 (square); DT1536 (triangle); DT1537 (inverted
triangle); DT1538 (diamond) and DT1539 (circle). (B) Eﬀect of Dz13 30 sequence positioning: ﬁrst 10 bases of Dz13 positioned in the middle
(DT1600; inverted triangle), at the 30 end (DT1601; diamond) or at the 30 end in reverse (DT1602; circle) were transfected along with Dz13 (square)
and Dz13scr (triangle). (C) Eﬀect of 30 tail length: ﬁrst 10 bases of Dz13 and an additional 5 (DT1544; triangle), 10 (DT1545; inverted triangle),
15 (DT1546; diamond), 20 (DT1547; circle) or 25 (DT1548; open square) random bases were transfected along with Dz13 (solid square). (D) Eﬀect of
decreasing retention of 50 terminal sequence: ﬁrst 10 (DT1548; square), 8 (DT1553; triangle), 6 (DT1554; inverted triangle) and 4 (DT1555; diamond)
bases of the Dz13 50 G-rich sequence with the balance made up with random nucleotides were transfected along with Dz13 (circle).
4566 Nucleic Acids Research, 2007, Vol. 35, No. 13analysis showed higher transfection at the higher cell
density (Figure 2B). These preliminary experiments
indicate selective cytotoxicity of Dz13 to proliferating
cells as opposed to those that are contact-inhibited and
non-proliferating.
Identification ofproteins binding to Dz13
In order to identify whether proteins bind the cytotoxic
ODNs and if binding correlated with cytotoxic potency,
protein pull-downs were performed using 30 biotinylated
congeners of Dz13 and Dz13scr (DT1309h and DT1310c,
respectively; Table 1) as ‘bait’. In HMEC-1 cytotoxicity
assays, these 30-biotinylated ODNs had very similar
cytotoxic properties to their untagged counterparts (data
not shown). For the pull-down experiments, the biotin-
ylated ODN was coupled to magnetic streptavidin beads
and a crossover design employed in which beads coupled
to the biotinylated ODN of interest were incubated with
HMEC-1 protein, washed with the opposite ODN and
eluted with the non-biotinylated bait ODN. That is, when
the beads were prepared with the biotinylated congener of
Dz13scr and loaded with cell protein extracts, they were
subsequently washed with a Dz13 solution and proteins
eluted with a Dz13scr solution. For the Dz13-coupled
beads, a large number of non-speciﬁc proteins were
washed oﬀ with Dz13scr and a number of strong staining
bands were obtained by competitive elution with Dz13,
Figure 2. Eﬀect of seeding density on cytotoxicity of Dz13. (A) A total of 50000 ARPE-19 cells per well were plated for high density and transfected
with 0–200nM Dz13 (circle) or Dz13scr (inverted triangle). A total of 4000 cells per well were plated for low density and transfected with Dz13
(triangle) or Dz13scr (square). Transfections were performed in triplicate and cellular proliferation measured 48h post-transfection. The data from
two independent experiments represent the mean survival as a percentage of untransfected cells from each of the densities +/  SD. (B) Examination
of transfection eﬃciency of DT1565 in low density and high density seeded HMEC-1 cells. Also, 2.6 10
5 (low density) or 3.25 10
6 (high density)
cells were seeded in 60mm dishes and mock-transfected or transfected with 100nM DT1565 (30 Oregon Green). Fluorescence was measured 24h later
in duplicate using ﬂuorescence-assisted cell sorting analysis (FACS).
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Elution with the non-cytotoxic Dz13scr yielded a large
number of bands including a predominant band at
 39kDa, however unlike Dz13, none of these were
speciﬁcally eluted by Dz13scr. Silver staining revealed a
lack of protein remaining bound to unconjugated beads
following extensive washing (data not shown).
In order to generate enough material to identify
proteins eluting from the beads, the experiment was
scaled up 5-fold and 1mg of protein was loaded onto
beads coupled to the biotinylated ODNs. In these
experiments, the number of washes was increased to 30
while the elution volume was kept constant. Following
concentration of the eluted fractions, the proteins were
digested with trypsin and analysed by LC-MS/MS, with
liquid chromatography used to separate the reasonably
complex mixture of peptides prior to mass spectrometric
analysis. A number of proteins eluting with both Dz13
and Dz13scr were identiﬁed (Table 2). Proteins identiﬁed
in the Dz13-eluting fraction (from Dz13-coupled beads)
included microtubule-associated protein 4 (MAP4),
nucleolin, vimentin, elongation factor 1A (eEF1A),
plasminogen activator inhibitor 1 (PAI-1) RNA-binding
protein, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and signal recognition particle 14kDa.
Proteins identiﬁed in the Dz13scr-eluting fraction (from
Dz13-coupled beads) included annexin II, GAPDH,
heterogeneous nuclear ribonuclear proteins A1, Lamin
A/C isoform 1 and nucleolin. The 51kDa band was
competitively eluted by Dz13 in three independent
experiments and eEF1A was identiﬁed in these fractions
by LC-MS/MS each time. Overall, a total of 10 peptides
from this protein were identiﬁed that together spanned
most of the protein sequence (Table 2). Western blotting
of pull-down proteins with an antibody directed to eEF1A
conﬁrmed that it was the major band identiﬁed by silver
staining at 51kDa and that the protein bound to both
Dz13 and Dz13scr beads but was only eluted by Dz13
(Figure 3B). The LC-MS/MS identiﬁcation of vimentin
was also conﬁrmed by western blots in which vimentin was
shown to bind to Dz-13 coupled beads as well as to
Dz13scr-coupled beads (data not shown). Elution of
vimentin from the beads with Dz13 or Dz13scr was not
detected by western (data not shown). This may reﬂect the
fact that more protein (5-fold) was loaded onto the beads
for LC-MS/MS analysis. Vimentin distribution within the
various cell compartments was assessed using cell fraction-
ation and western blotting 24h post-transfection with
Dz13 and Dz13scr. Vimentin was mostly localized to the
cytoskeletal and nuclear fractions and this distribution did
not appear to be modiﬁed 6 or 24h following transfection
with 200 nM Dz13 (data not shown).
Figure 3. Pull-down experiments using total protein lysates from
HMEC-1 cells. HMEC-1 protein extract was incubated with biotiny-
lated Dz13 (left lanes) or Dz13scr (right lanes) coupled to streptavidin
beads and proteins eluted with either 1mM Dz13scr or 1mM Dz13 as
indicated. The beads were washed three times with binding buﬀer
between ODN elutions. Protein fractions were concentrated, electro-
phoresed and bands revealed by silver staining (A) or by eEF1A
western (B). E1 indicates elution #1 and unbound refers to residual
proteins in ﬂow-through following capture of proteins to beads. The
approximate molecular weight (kDa) is indicated.
Table 2. Proteins binding to Dz13 and Dz13scr identiﬁed by LC-MS/MS
Ensembl Gene ID Protein Number of peptides matched Predicted MW (kDa)
Dz13-eluted proteins
ensg00000140319 Signal recognition particle 14kDa 2 14
ensg00000156508
  Elongation factor 1A 10 51
ensg00000101210
 
ensg00000026025 Vimentin 2 54
ensg00000047849 Microtubule associated protein 4 2 121
ensg00000142864 Plasminogen activator inhibitor -1 RNA-binding protein 1 42
ensg00000111640 Glyceraldehyde 3 phosphate dehydrogenase 1 36
ensg00000115053 Nucleolin 1 77
Dz13scr-eluted proteins
ensg00000182718 Annexin II 2 39
ensg00000111640 Glyceraldehyde 3 phosphate dehydrogenase 3 36
ensg00000135486 Heterogeneous nuclear ribonuclear protein A1 3 22
ensg00000160789 Lamin A/C isoform 1 1 80
ensg00000115053 Nucleolin 1 77
 Peptides identiﬁed by MS are found in both eEF1A1 and eEF1A2.
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In order to further deﬁne the role of eEF1A in the
cytotoxic mechanism of Dz13 and to determine whether
cytotoxicity correlates with eEF1A binding, pull-down
assays were performed where active and inactive oligo-
deoxynucleotides were used to elute proteins bound to
Dz13. DT1501 (rat c-jun Dz13 homologue) and Dz13scr
are non-cytotoxic to HMEC-1 cells under the conditions
used here (15). Cytotoxicity experiments were performed
with a GT-rich oligodeoxynucleotide (DT1605; Table 1)
previously reported as binding to eEF1A and inducing
cytotoxicity in human T-lymphoblasts (11). However,
this GT ODN was not cytotoxic to HMEC-1 cells at
concentrations of up to 200nM (data not shown). The
oligodeoxynucleotides DT1595 (AGGG repeat), Rs6
(DT1556) and NT36 (DT1577; ATM-inducing) all
resulted in signiﬁcant cytotoxicity to HMEC-1 cells (15).
Elution of eEF1A from Dz13-coupled beads occurred
for all the cytotoxic oligodeoxynucleotides tested
(Figure 4). In contrast, elution of eEF1A using non-
cytotoxic oligodeoxynucleotides was very poor (Figure 4).
Nevertheless, when Dz13 was subsequently used as an
eluting solution, eEF1A was strongly released from beads
that had been ﬁrst eluted with the non-cytotoxic
oligodeoxynucleotides Dz13scr and DT1501, and to a
lesser extent with DT1605. eEF1A was only weakly
released by Dz13 from beads where eEF1A had been
strongly eluted using the cytotoxic oligodeoxynucleotides
DT1595, DT1577 and DT1556 (Figure 4). This demon-
strates that eEF1A initially captured by the biotinylated
Dz13 beads and only weakly released by the non-cytotoxic
ODN could still be released with Dz13 solutions.
To determine the cellular localization of the eluting
eEF1A, the pull-down procedure was performed on the
cytoplasmic, nuclear, membrane and cytoskeletal fractions
of HMEC-1 cells. Whereas eEF1A from the cytoplasmic,
nuclear and membrane/organelle fractions bound to Dz13
beads, the major source of eEF1A eluted by Dz13 was
from the cytoplasm (Figure 5). Pull-downs were also
performed with total protein lysates from a number of
other cell lines including RSMC, HEK-293 and HCT-116,
to which Dz13 is cytotoxic (15). Predominant elution by
Dz13 of the 51kDa band was observed in all cases and this
band was conﬁrmed as being eEF1A by western blotting
(data not shown). The results indicate that eEF1A binding
also occurs in other cell lines in which Dz13 is cytotoxic.
When examined directly by western blotting, the
Figure 4. Elution of eEF1A from Dz13-beads using cytotoxic and non-cytotoxic ODNs. Following binding of HMEC-1 proteins to Dz13-beads,
proteins were eluted twice using 1mM of the indicated ODN. Before secondary elution with 1mM Dz13 the beads were washed three times with
binding buﬀer. Proteins were electrophoresed and the gels (A) silver-stained or (B) transferred to PVDF membrane and probed for eEF1A. Lanes
labelled ‘beads’ refers to proteins left bound to beads after wash and elutions steps. The experiment was performed twice and the data presented have
been compiled from separate gels but are representative results from a single experiment. E refers to ‘Elution’ and the approximate molecular weight
(kDa) is indicated.
Figure 5. Binding of eEF1A from diﬀerent cellular fractions of
HMEC-1 cells. Protein pull-downs using Dz13-beads were performed
on cytoplasmic, nuclear and membrane/organelle fractions. 1, eEF1A
bound to Dz13-beads; 2, eEF1A eluting from Dz13 beads with 1mM
Dz13; 3, eEF1A eluting from Dz13-beads protein with 1mM Dz13scr.
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and was not aﬀected by treatment with Dz13 for 24h
(data not shown).
The amount of eEF1A eluted with Dz13 was concen-
tration dependent in that a concentration of 10mM Dz13
eluted more eEF1A than a concentration of 1mM (data
not shown). Nevertheless, in all experiments elution was
only partial, and residual eEF1A was found associated
with beads post elution (Figures 3 and 4). This suggests
that the interaction might not be canonical or that eEF1A
undergoes a conformational change upon binding that
inhibits its release. In addition to in vitro binding
experiments, cells were transfected with 100 nM biotin-
ylated Dz13 and Dz13scr and pull-downs performed
directly on cell extracts. There was binding of eEF1A to
both Dz13 and Dz13scr beads (data not shown), conﬁrm-
ing the presence of the interaction of both oligodeoxynu-
cleotides when the binding occurs within the cells.
Furthermore, despite the high abundance of eEF1A, a
possible interaction between Dz13 and eEF1A directly in
cells was demonstrated using ﬂuorescence colocalization
experiments (Figure S2).
DISCUSSION
Whilst there are a number of reports describing the
cytotoxic nature of certain oligodeoxynucleotides,
in particular G-rich oligodeoxynucleotides (see
Introduction Section), there is little known about the
motif or sequence requirements for cytotoxicity. The
current study attempted to deﬁne further the exact
requirements for cytotoxicity and identify proteins
involved in binding to these oligodeoxynucleotides,
thereby unravelling the mechanisms involved in the
eventual cytotoxicity of the molecules.
We determined that the 50 sequence, the core or the tail
of Dz13 alone are insuﬃcient to regenerate the cytotoxic
activity of Dz13 against HMEC-1 cells, thereby indicating
a length and/or sequence requirement. We used the novel
strategy of testing pools of oligodeoxynucleotides
comprised of random sequences along with the 50 G-rich
elements of Dz13 and Rs6 in various position and length
contexts to demonstrate that the G-rich element needs to
be present at the 50 extremity and be followed by a tail
component that is preferably composed of mixed nucleo-
tides. A comparison of the active oligodeoxynucleotides,
in combination with the 50-motif reduction experiment,
leads us to conclude that the required 50 sequence is
G-rich, composed of 6–9nt with at least four consecutive
purines. The presence of a triple G motif (G-G-G)
provides for the greatest potency and the 50 extremity of
the triple G motif needs to be positioned no more than 3nt
from the 50 end of the ODN. We have previously shown by
CD that Dz13 does not assemble into stable secondary
structures in vitro (15). Nevertheless, substitution of any of
the guanosines in the triple G motif of Dz13 abrogated its
cytotoxic activity (15). This suggests that the hydrogen
bonding activity of these guanosines does not lead to
G-quadruplex formation, but is nevertheless required for
cytotoxicity, perhaps by enhancing binding of the
oligodeoxynucleotides to intracellular proteins. The tail
sequence requirements were intriguing in that most
sequences with some degree of ‘complexity’ supported
cytotoxic activity, but some individual tail sequences, in
particular those free of guanosines, had reduced activity.
It is possible that the less complex tail sequences such as
the polydA tail are being sequestered by polydA-binding
proteins thereby abrogating cytotoxicity. Wu et al. (22)
have previously demonstrated that tail sequence and
complexity encourages the multimeric aggregation of the
oligodeoxynucleotides, thereby activating TLR9 and
cell uptake. However, we have previously demonstrated
a need for transfection and ruled out endosomal TLR
engagement in the mechanism of action of Dz13 and Rs6
against HMEC-1 cells (15). Therefore, although multi-
meric assembly remains a possibility, it is unlikely to relate
to uptake and TLR engagement.
We previously compared the activity of Dz13, a
prototypic G-rich oligodeoxynucleotide, with that of
other published sequences including NT36, an ATM-
inducing oligodeoxynucleotide (23) and 20AG, an
oligodeoxynucleotide originally designed to be a triplex-
forming inhibitor of K-ras (17). Both of these oligodeoxy-
nucleotides have purine tracts in the 50 sequence and NT36
is of comparable length to the active ODNs described in
the present study. As shown for Dz13, the potency of the
shorter 20AG ODN was length dependent. That is, the
cytotoxicity of the AG molecule increased as the length of
the molecule increased.
ODNs have been proposed to exert their cytotoxicity
through speciﬁc interaction with cellular proteins such as
nucleolin (24) and eEF1A (7). Nucleolin was identiﬁed
as one of the proteins that bound to Dz13 and Dz13scr.
The absence of an eﬀect on HMEC-1 proliferation by the
nucleolin-binding oligodeoxynucleotide GRO29A pro-
vided further evidence for the lack of direct involvement
of nucleolin in Dz13-mediated cytotoxicity. Likewise, a
representative from a class of GT-rich ODNs, which
reportedly binds eEF1A and is cytotoxic to human
T-lymphoblasts (11), was not cytotoxic to HMEC-1
cells. Furthermore in our experiments, the GT oligodeoxy-
nucleotide did not displace eEF1A from Dz13 capture
beads as potently as Dz13 or the other cytotoxic ODNs
tested, indicating that it has less binding aﬃnity to the
eEF1A found in this cell line. The ODNs described in the
present study therefore represent a novel class of potently
cytotoxic molecules.
The ability of several of the proteins, including eEF1A
to bind competitively to the cytotoxic oligodeoxynucleo-
tides and not be eluted by the non-cytotoxic ODNs in vitro
suggests that the ODNs may competitively bind to
proteins within the cells and that this is mechanistically
relevant to the cytotoxicity of the molecule. eEF1A is an
extremely abundant protein with a multitude of roles
including protein synthesis, stress-sensing, apoptosis and
cellular proliferation (25,26). Scaggiante et al. (7) recently
reported a correlation between eEF1A binding and
cytotoxicity of G-rich oligodeoxynucleotides that is
independent of secondary structure formation. They also
reported that some non-cytotoxic G-rich oligodeoxynu-
cleotides bind eEF1A to a small degree in the absence
4570 Nucleic Acids Research, 2007, Vol. 35, No. 13of competitor (7). The fact that both Dz13 and Dz13scr
were able to bind eEF1A in vitro and in cells indicates
that some of the captured eEF1A is also binding via a
non-speciﬁc mechanism in HMEC-1 cells. However, the
selective release of eEF1A from Dz13 capture-beads with
those ODNs that are cytotoxic suggests that there is
a relationship between eEF1A binding and cytotoxicity.
eEF1A has been proposed to act as a signalling
molecule in proliferating cells through the binding of
other nucleic-acid-binding proteins such as ZPR1 (27)
followed by translocation to the nucleus. Once inside the
nucleus eEF1A has the capacity to bind DNA, RNA and
RNA polymerase and therefore potentially plays a role in
transcriptional regulation. Binding of eEF1A to Dz13 was
observed in nuclear, cytoplasmic, membrane/organelle
and cytoskeletal fractions; cytoplasmic eEF1A eluted
most strongly from Dz13 beads. This could reﬂect a
greater concentration of DNA-binding proteins in the
nuclear fraction and consequently a greater number of
proteins eluting in general or that nuclear eEF1A has a
higher aﬃnity for Dz13. It is possible that the higher
aﬃnity cytotoxic oligodeoxynucleotides displace eEF1A
from nuclear or cytoplasmic protein complexes such as
the nuclear cytotoxicity-related complex (CRC; 7),
thereby inhibiting the normal functioning of eEF1A in
the cell, resulting in a reduction in cellular proliferation
and eventually cell death.
Vimentin was also identiﬁed in the pull-down assay.
Vimentin has been shown to bind to G-rich ODNs,
causing the translocation of the vimentin–DNA complex
to the nucleus (28). However, this was not evident in
HMEC-1 cells transfected with Dz13. Collectively the
protein pull-down experiments indicate that binding
of cytotoxic ODNs to eEF1A and other proteins is
potentially a key event in the mechanism of action of the
molecules.
In conclusion, we have determined that ODNs such as
Dz13 and Rs6 which were initially designed as catalytic
DNAzymes, belong to a group of cytotoxic G-rich ODNs
with novel sequence and length requirements. Although
the mechanism is unclear, it is likely to be mediated
through binding to eEF1A. These molecules are prefer-
entially active against proliferating cells and therefore
constitute part of a new class of potentially useful
molecules for the treatment or investigation of diseases
characterized by abnormal cell proliferation.
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